The role of platelet function testing in risk stratification and clinical decision-making

Paul A. Gurbel, Udaya S. Tantry

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Clopidogrel (a widely used second-generation thienopyridine) therapy is associated with an unpredictable pharmacodynamic response whereby approximately 1 in 3 patients will have a high on-treatment platelet reactivity to adenosine diphosphate. High on-treatment platelet reactivity is an established risk factor for ischemic event occurrence in patients undergoing percutaneous coronary intervention. Platelet function testing may have a role in monitoring therapeutic efficacy when clopidogrel is the chosen agent and in safety when more potent drugs are used, especially in patients with high bleeding risk. At this time, it seems most reasonable to assess platelet function in high-risk clopidogrel-treated patients.

Original languageEnglish (US)
Pages (from-to)607-614
Number of pages8
JournalInterventional Cardiology Clinics
Issue number4
StatePublished - Oct 2013


  • Bleeding
  • Clopidogrel
  • High on-treatment platelet reactivity
  • P2Y receptor
  • Percutaneous coronary intervention
  • Platelet function testing

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'The role of platelet function testing in risk stratification and clinical decision-making'. Together they form a unique fingerprint.

Cite this